drugset / Trial / NCT01296256
Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Bendamustine in combination with Etoposide, Cytarabine and Melphalan (BeEAM) are effective as conditioning followed by ASCT in patients with aggressive lymphoma.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 200 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 400 mg/m2 | — |
| Subject | Etoposide | Small molecule | 200 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |